Crizotinib: an anaplastic lymphoma kinase inhibitor

By Gadgeel Shirish M   Bepler Gerold  

Future Oncology, Vol. 7, Iss. 8, 2011-08 ,pp. : 947-953

Future Medicine

Access to resources Recommend Favorite

Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 3, 2010-03 ,pp. : 236-249

Bentham Science Publishers

Access to resources Recommend Favorite

Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report

By                  

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 889-891

Science Publishers

Access to resources Recommend Favorite

Diagnostic and therapeutic issues for patients with advanced nonsmall cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (Review)

By        

International Journal of Oncology, Vol. 45, Iss. 2, 2014-01 ,pp. : 509-515

Spandidos Publications

Access to resources Recommend Favorite

Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?

By Franco Renato   Rocco Gaetano   Marino Federica Zito   Pirozzi Giuseppe   Normanno Nicola   Morabito Alessandro   Sperlongano Pasquale   Stiuso Paola   Luce Amalia   Botti Gerardo   Caraglia Michele  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 4, 2013-04 ,pp. : 407-420

Informa Healthcare

Access to resources Recommend Favorite